Protease Inhibitors in Neurologic Diseases

  • Noriaki Adachi
Part of the NATO ASI Series book series (NSSA, volume 191)


Proteases and their inhibitors are known or suspected to be implicated in many aspects of normal physiology and disease processes. Although the etiologies of all neurological diseases are not yet known, many are fatal and can be classified as hereditary. Among them are amyotrophic lateral scleroses (ALS) and familial amyloidotic polyneuropathy (FAP). FAP is encountered often in our clinical work at Shinshu University School of Medicine because our hospital is located in one of the areas reporting the highest incidence of FAP in the world, second only to Portugal. Therefore, myself and my colleagues have taken a special interest in investigating the states of proteases and their inhibitors in neurologic diseases. This chapter briefly summarizes our current state of knowledge concerning the implications of protease and protease inhibitors in ALS and FAP. These developments should provide insights for subsequent steps toward clarifying the etiologies of these diseases.


Amyotrophic Lateral Sclerosis Familial Mediterranean Fever Amyloid Fibril Interstitial Cystitis Experimental Allergic Encephalomyelitis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    J.P. Antel, E. Chelmicka Schorr, M. Sportiello, K. Stefansson, R.L. Wollman, and B. G. W. Arnason, Muscle acid protease activity in amyotrophic lateral sclerosis: correlation with clinical and pathologic features. Neurology, 32: 901–903 (1982).CrossRefPubMedGoogle Scholar
  2. 2.
    R.L. Beach, L.S.Rao, B.W.Festoff, E.T. Reyes, R.Yanagihara, and D. C.Gajdusek, Collagenase activity in skin fibroblasts of patients with amyotrophic lateral sclerosis. J. NeuroL Sci, 72: 49–60 (1986).CrossRefPubMedGoogle Scholar
  3. 3.
    B.W. Festoff, Circulating protease inhibitors in amyotrophic lateral sclerosis: reduced a2 macroglobulin. Ann. NeuroL, 8: 121 (1980).Google Scholar
  4. 4.
    B.W. Festoff, Occurrence of reduced aZ macroglobulin and lowered protease inhibiting capacity in plasma of amyotrophic lateral sclerosis patients. Ann. N.Y. Acad Sci., 421: 369–376 (1983).CrossRefPubMedGoogle Scholar
  5. 5.
    N. Adachi, and S. Shoji, Studies of protease inhibitors in the sera of patients with amyotrophic lateral sclerosis. J. NeuroL Sci., 89: 165–168 (1989).CrossRefPubMedGoogle Scholar
  6. 6.
    C. Andrade, A peculiar form of peripheral neuropathy:familial atypical generalized amyloidosis with special involvement of the peripheral nerves. Brain, 75: 408–427 (1952).CrossRefPubMedGoogle Scholar
  7. 7.
    S. Araki, S. Mawatari, M. Ohta, A. Nakajima, and Y. Kuroiwa, Polyneuritic amyloidosis in a Japanese family. Arch. NeuroL, 18: 593–602 (1968).CrossRefPubMedGoogle Scholar
  8. 8.
    M.D. Benson, and A.S. Cohen, Generalized amyloid in a family of Swedish origin. Ann. Intern. Med., 86: 419–424 (1977).PubMedGoogle Scholar
  9. 9.
    P.P. Costa, A.S. Figueira, and F. R. Bravo, Amyloid fibril protein related to prealbumin in familial amyloid polyneuropathy. Proc. Natl. Acad. Sci. USA, 75: 4499–4503 (1978).CrossRefPubMedGoogle Scholar
  10. 10.
    M. Pras, F. Prelli, E.C. Franklin, and B. Fragione, Primary structure of an amyloid prealbumin variant in familial polyneuropathy of Jewish origin. Proc. NatL Acad. Sci. USA, 80: 539–542 (1983).CrossRefPubMedGoogle Scholar
  11. 11.
    S. Tawara, M. Nakazato, K. Kangawa, H. Matsuo, and S. Araki, Identification of amyloid prealbumin variant in familial amyloidotic polyneuropathy (Japanese type). Biochem. Biophys. Res. Commun., 116: 880–888 (1983).CrossRefPubMedGoogle Scholar
  12. 12.
    M.J.M. Saraiva, S. Birken, P.P. Costa, and D.S. Goodman, Amyloid fibril protein in familial amyloidotic polyneuropathy, Portuguese type. J Clin Invest 74: 104–19 (1984).CrossRefPubMedGoogle Scholar
  13. 13.
    F.E. Dwulet, and M.D. Benson, Primary structure of an amyloid prealbumin and its plasma precursor in a heredo-familial polyneuropathy of Swedish origin. Proc Nat Acad Sci USA 81: 694–98 (1984).CrossRefPubMedGoogle Scholar
  14. 14.
    S. Mita, S. Maeda, K. Shimada, and S. Araki, Cloning and sequence analysis of cDNA for human prealbumin. Biochem Biophys Res Commun 124: 558–64 (1984).CrossRefPubMedGoogle Scholar
  15. 15.
    M.J.M. Saraiva, P.P. Costa and D.S. Goodman, Genetic expression of a transthyretin mutation in typical and late-onset Portuguese families with familial amyloidotic polyneuropathy. Neurology, 36: 1413–1417 (1986).CrossRefPubMedGoogle Scholar
  16. 16.
    G. Holmgren, E. Haettner, I. Nordenso, O.L. Sandgren, L. Steen, and E. Lundgren, (1988) Homozygosity for the transthyretin-met30-gene in two Swedish sibs with familial amyloidotic polyneuropathy. Clin Genet (Denmark) 34 (5) p333–8.Google Scholar
  17. 17.
    I. Kedar, M. Ravid, and E. Sohar, Demonstration of amyloid degrading activity in normal human serum. Proc. Soc. Exp. BioL Med., 145: 343–345 (1974).PubMedGoogle Scholar
  18. 18.
    O. Wegelius, A.M. Teppo, and C.P.J. Maury, Reduced amyloid A-degrading activity in serum in amyloidosis associated with rheumatoid arthritis. Br. Med. J., 284: 617–619 (1982).CrossRefGoogle Scholar
  19. 19.
    B. Skogen, and L. Natvig, Degradation of amyloid proteins by different serine proteases. Scand. J. ImmunoL, 14: 389–396 (1981).CrossRefPubMedGoogle Scholar
  20. 20.
    N. Adachi, S.Shoji, S.Nakagawa, C-S.Koh, N.Tsukada and N.Yanagisawa, Studies of protease and protease inhibitors in familial amyloidotic polyneuropathy. J. NeuroL Sci., 81: 79–84 (1987).CrossRefPubMedGoogle Scholar
  21. 21.
    M. Howell, Acquired factor X deficiency associated with systemic amyloidosis: report of a case. Blood 21: 739–744 (1963).PubMedGoogle Scholar
  22. 22.
    J.R. Krause, Acquired factor X deficiency and amyloidosis. Am. J. Clin. Path. 67: 170–173 (1977).PubMedGoogle Scholar
  23. 23.
    M. Quitt, E. Aghai, D. Miriam, R. Kohan, Y.B. Ari, and P. Froom, Acquired factor X and antithrombin III deficiency in a patient with primary amyloidosis and nephrotic syndrome. Scand. J. HaematoL 35: 155–157 (1985).CrossRefPubMedGoogle Scholar
  24. 24.
    B. Furie, E. Greene, and B.C. Furie, Syndrome of acquired factor X deficiency and systemic amyloidosis: in vivo studies of the metabolic fate of factor X. New Engl. J. Med. 297: 81–85 (1977).CrossRefPubMedGoogle Scholar
  25. 25.
    RA. McPherson, J.W. Onstad, R.J. Ugoretz, and P.L. Wolf, Coa-gulopathy in amyloidosis: combined deficiency of factors IX and X. Am. J. HematoL 3: 225–235 (1977).PubMedGoogle Scholar
  26. 26.
    N. Adachi, C.S. Koh, N. Tsukada, S. Shoji, and N. Yanagisawa, In vitro degradation of amyloid material by four proteases in tissue of a patient with familial amyloidotic polyneuropathy. J.NeuroL Sci, 84:295–299 (1988).Google Scholar
  27. 27.
    T. Isobe, and E.F. Osserman, Effects of dimethyl sulphoxide (DMSO) on Bence-Jones proteins, amyloid fibrils and casein-induced amyloidosis. In: Wegelius O, Pastemack A, eds. Amyloidosis. London, New York and San Francisco: Academic Press, 1976:247–57 (1976).Google Scholar
  28. 28.
    H. Falck, and O. Wegelius, Treatment of secondary renal amyloidosis with dimethyl sulphoxide. In: Proceedings of European Amyooidosis Research Symposium. Bristol, Sept 10–12, 1981.Google Scholar
  29. 29.
    I. Kedar, E. Sohar, and M. Ravid, Degradation of amyloid by a serum component and inhibition of degradation. J. Lab. Clin. Med., 99: 693–700 (1982).PubMedGoogle Scholar
  30. 30.
    B. Skogen,and E. Amundsen, Degradation of amyloid proteins with protease I from Aspergillus oryzae. In vivo increase in SAA clearance rate after enzyme infusion. Scand. J. ImmunoL 16, 509–514 (1982).Google Scholar
  31. 31.
    N. Adachi, S. Shoji, and N. Yanagisawa, Bleeding Manifestations in 24 Patients with Familial Amyloidotic Polyneuropathy. Europ. NeuroL 28: 115–116 (1988).CrossRefPubMedGoogle Scholar
  32. 32.
    T. Kobayashi, H. Ozone, H. Kamei, and K. Ishimaru, Chymoral for inflammatory diseases in the orodental area. Shikai Tenbo. 64 (4): 813–8 (1984).PubMedGoogle Scholar
  33. 33.
    P.H. Brakenbury, and J. Kotowski, A comparative study of the management of anlde sprains. Br J Clin Pract. 37 (5); 181–5 (1983).PubMedGoogle Scholar
  34. 34.
    A.D. Roberts, and D.M. Hart, Polyglycolic acid and catgut sutures, with and without oral proteolytic enzymes, in the healing of episiotomies. Br J Obstet Gynaecol. 90 (7); 650–3 (1983).CrossRefPubMedGoogle Scholar
  35. 35.
    V.G. Glozman, and I.S.Anchupane, Use of chymotrypsin in inflammatory diseases of the scrotal organs. Urol Nefrol (Musk). (5): 44–6 (1982).Google Scholar
  36. 36.
    S. Avakian, Current concepts in therapy. Chymotrypsin and trypsin. N F.ngl J Med. (1961).Google Scholar
  37. 37.
    R.D. Rodewald, Selective antibody transport in the proximal small intestine of the neonatal rat. J Cell Biol 45: 635–40 (1970).CrossRefPubMedGoogle Scholar
  38. 38.
    A. Stochino, G. Tecce, and G.G. Tedeschi, Sull’assorbimento intestinal delle proteine omologhe ed eterologhe. Boll Soc ltal Biol Sper 27: 1672–4 (1951).Google Scholar
  39. 39.
    J.M. Payne, B.F. Sansom, R.J. Garner, A.R. Thomson, and B.J. Miles, Uptake of small resin particles (1–5 microns diameter) by alimentary canal of calf. Nature (London) 188: 586 (1960).CrossRefGoogle Scholar
  40. 40.
    RA. Bruce, and K.C. Quinton, Effect of oral a-chymotrypsin on sputum viscosity. Br Med J, 1: 282284 (1962).Google Scholar
  41. 41.
    B.L. Kabacoff, A. Wohhnan, M. Umkey, and S. Avakian, Absorption of chymotrypsin from the intestinal tract. Nature, 199: 815 (1963).CrossRefPubMedGoogle Scholar
  42. 42.
    S. Avakian, Further studies on the absorption of chymotrypsin. Clin Pharmacol Ther, 5: 712–5 (1964).PubMedGoogle Scholar
  43. 43.
    C.R. Abraham, D. J. Selkoe and H. Potter, Immunochemical identification of the serine protease inhibitor, at-antichymotrypsin, in the brain amyloid deposits of Alzheimer’s disease. Cell, 52: 487501 (1988).Google Scholar
  44. 44.
    C.S. Koh, and P.Y. Paterson, Suppression of Clinical Signs of Cell Transferred Experimental Allergic Encephalomyelitis and Altered Cerebrovascular Permeability in Lewis Rats Treated with a Plasminogen Activator Inhibitor. Cellular Immunology 107, 52–63 (1987).CrossRefPubMedGoogle Scholar
  45. 45.
    L.G. Millard, and N.R. Rowell, Primary amyloidosis and myelomatosis associated with excessive fibrinolytic activity. Br. J. Derm. 94: 569–571 (1976).CrossRefGoogle Scholar
  46. 46.
    L.S. Perlin, P. Brakman, H.S. Berg, P.I. Kirchner, R.B. Moguin, T. Astrup, Enhanced blood coagulation and fibrinolysis in a patient with primary fibrinolysis. Thromb Haemostasis 26: 9–14 (1971).Google Scholar

Copyright information

© Plenum Press, New York 1990

Authors and Affiliations

  • Noriaki Adachi
    • 1
  1. 1.Department of Medicine (Neurology)Shinshu University School of Medicine3-1-1, Asahi Matsumoto 390Japan

Personalised recommendations